Genzyme Investors Sue Company For Rejecting Sanofi Bid
Boston, MA, United States (AHN) – Two investors of Genzyme Corp. are suing the biotechnology company for rejecting an $18.5 billion takeover offer from Sanofi Aventis.
According to Bloomberg, the investors have filed a lawsuit in a Boston court accusing Genzyme of depriving investors the right to “to receive maximum value for their shares.”
Sanofi began a hostile takeover of the Massachusetts-based company early this month. The French pharmaceutical giant made a non-binding offer in July to acquire all of Genzyme’s outstanding shares of common stock for $69 per share.
Genzyme chief executive officer and board chairman Henri Termeer had deemed the price too low and called the offer “opportunistic.”
Termeer had sought a better offer, citing Genzyme’s plans to reduce costs and raise production, and the firm’s outlook for its multiple sclerosis drug, alemtuzumab, as well as for Cerezyme, which is for patients with Gaucher disease, and Fabrazyme for those suffering Fabry disease.
Genzyme’s board last week unanimously rejected the latest proposal from Sanofi because the bid is “based on identical financial terms to two previous unsolicited proposals.”
“The offer fails to compensate shareholders for the value of Genzyme’s existing business, which delivered compound annual revenue growth of 23 percent from 2002-2009,” the board added. “The offer price does not adequately compensate Genzyme’s shareholders for the strategic importance and financial benefit to Sanofi-Aventis of a potential transaction with Genzyme.”
The board urged shareholders not to take action, saying a program had been initiated to inform them of “intrinsic value of the company.”
Sanofi insists the amount represents a premium of 38 percent over Genzyme’s unaffected share price of $49.86 on July 1. The drug maker also said discussions with shareholders who own more than 50 percent of Genzyme revealed that shareholders were “frustrated” with the biotech firm’s “persistent refusal to have meaningful discussions.”
Genzyme is one of the world’s largest biotech companies. Founded in Boston in 1981, it specializes in producing drugs for rare genetic disorders, transplant and immune diseases, and cancer.
View full post on Economy, Business And Finance Stories
